Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
PPPropanc Biopharma, Inc. logo

Propanc Biopharma, Inc. (PPCB)

NASDAQ Capital Market · Currency in USD
$2.29 ▼ -0.51 (-18.21%)
At close: Oct 26, 4:00 PM ET. Market closed.
$2.20 ▼ -0.09 (-3.93%)
After hours: Oct 26, 7:59 PM ET

Summary

Previous Close
$2.80
Open
$3.00
Day's Range
$2.26 – $3.01
52 Week Range
$2.21 – $379.80
Volume
100,161
Avg. Volume
2,005,027
Market Cap
$521.75K
Beta (5Y Monthly)
3.33
PE Ratio (TTM)
--
EPS (TTM)
-$16.79
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Propanc Biopharma, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
2
CEO
James Nathanielsz

Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer.

Earnings

DateEst.Actual
Oct 5, 2026–-$4.07
May 14, 2026–-$7.00
Feb 17, 2026–-$7.50
Nov 14, 2025–-$9.75
Sep 29, 2025–-$8.75
May 15, 2025–-$312.50

Similar stocks

Get free alerts on PPCB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.